Workup and Treatment Strategy for Cervical, Endometrial, and Ovarian Cancers
The workup and treatment of gynecologic cancers must be cancer-specific and stage-directed, with surgery as the primary modality for early disease, combined chemoradiation for locally advanced cervical cancer, and risk-stratified adjuvant therapy for endometrial cancer based on molecular and histopathologic features.
ENDOMETRIAL CANCER
Initial Workup
- Chest X-ray
- Transvaginal ultrasound to assess myometrial invasion depth
- Contrast-enhanced dynamic MRI (best modality for assessing uterine and locoregional pelvic extension)
- Blood counts, liver and renal function profiles
- CT scan of abdomen/retroperitoneal nodes if extra-uterine spread suspected
Critical caveat: Preoperative endometrial sampling changes diagnosis (type/grade) in up to 25% of cases at final pathology 2.
Risk Stratification (Stage I Disease)
Classify patients into three prognostic groups based on FIGO stage, grade, depth of myometrial invasion, and histology 1, 2:
Low Risk:
- Stage Ia/Ib, grade 1-2, endometrioid histology
- Treatment: Surgery alone, no adjuvant therapy 1
Intermediate Risk:
- Stage Ic, grade 1-2, endometrioid OR Stage Ia/Ib, grade 3, endometrioid
- Treatment: Adjuvant pelvic radiotherapy reduces pelvic/vaginal relapses but does NOT improve overall survival 1
- Exception: Patients ≥60 years with deeply invasive G1-2 or superficial G3 tumors have >15% locoregional relapse rate—recommend adjuvant pelvic ± intravaginal radiotherapy 2
High Risk:
- Stage Ic, grade 3, endometrioid OR any stage with serous, clear cell, small cell, or undifferentiated histology
- Treatment: Pelvic radiotherapy for locoregional control PLUS platinum-based chemotherapy, which significantly improves overall survival and progression-free survival compared to radiotherapy alone 2
Stage II Treatment
- Stage IIa: Treat as Stage I based on other risk factors 1
- Stage IIb: Extended radical hysterectomy, bilateral salpingo-oophorectomy, and lymph node dissection, followed by adjuvant pelvic ± intravaginal radiotherapy if high-risk features present 1
Do NOT use progestational agents as adjuvant therapy in low-stage disease—they do not improve survival 1.
Advanced Disease (Stages III-IV)
- Maximal surgical cytoreduction in patients with good performance status 1
- Stage III based solely on positive peritoneal cytology: Treat as Stage I/II based on other clinicopathologic data 1
- Systemic therapy: Cisplatin + doxorubicin combination significantly improves progression-free survival and overall survival in optimally debulked Stage III-IV disease compared to whole abdominal radiation 1
- Alternative regimen: Carboplatin + paclitaxel (lower toxicity, reasonable alternative) 1
- Progestational agents (medroxyprogesterone acetate 200 mg daily) active in steroid receptor-positive tumors (mostly G1-2 lesions) 1
Follow-Up Protocol
Most recurrences occur within 3 years 1:
- Years 1-3: Every 3-4 months with history, physical, and gynecological examination
- Years 4-5: Every 6 months
- After year 5: Annually
Focus on vaginal/pelvic examination since many relapses are isolated and potentially curable if detected early. Routine PAP smears and systematic radiography are of unproven benefit 1.
CERVICAL CANCER
Workup
Based on NCCN guidelines 3:
- Clinical examination with careful assessment of tumor size, parametrial involvement, and vaginal extension
- Imaging (MRI pelvis preferred) for local staging
- Chest imaging to exclude metastases
- Consider PET-CT for advanced disease
Treatment by Stage
Early Stage (IA1-IB1, tumors <2 cm without high-risk features):
- Fertility-sparing options available for carefully selected patients 4
- Sentinel lymph node biopsy is safe and effective alternative to systematic lymphadenectomy 5
Locally Advanced Disease:
- Definitive combined chemoradiation is the standard of care 6
- Improves overall survival and disease-free survival compared to radiation alone
- Recent breakthrough: Pembrolizumab added to definitive chemoradiotherapy sets new benchmark 7
Recurrent/Metastatic Disease:
- Immunotherapy combinations showing promise
- Refer to full NCCN guidelines for detailed recommendations 3
OVARIAN CANCER
Surgical Approach
Primary Debulking Surgery vs. Neoadjuvant Chemotherapy:
- Primary debulking surgery is superior to neoadjuvant chemotherapy followed by interval debulking in fit patients treated at experienced centers 5
- Maximal cytoreduction is the goal
Systemic Therapy
Advanced Disease:
- Platinum-based chemotherapy backbone
- Consider weekly paclitaxel with carboplatin and bevacizumab in high-risk disease (ICON8B data) 7
Platinum-Resistant Disease: Major advances in 2025 7:
- Mirvetuximab soravtansine (folate receptor-α antibody-drug conjugate): Overall survival benefit in high-expressing tumors
- Trastuzumab deruxtecan: Expands actionable HER2 disease, greatest activity in 3+ immunohistochemistry tumors
- Combination strategies: Relacorilant + nab-paclitaxel; pembrolizumab + weekly paclitaxel ± bevacizumab showing survival signals
Borderline Ovarian Tumors and Germ Cell Tumors:
- Fertility-sparing treatment broadly supported for carefully selected patients 4
KEY PITFALLS TO AVOID
Do NOT rely solely on preoperative endometrial biopsy—25% discordance rate with final pathology 2
Do NOT use progestational agents as adjuvant therapy in low-stage endometrial cancer—no survival benefit 1
Do NOT perform systematic lymphadenectomy in early cervical cancer when sentinel lymph node biopsy is available and appropriate 5
Do NOT choose neoadjuvant chemotherapy over primary debulking in fit ovarian cancer patients at experienced centers 5
Do NOT overlook molecular classification in endometrial cancer—increasingly informs risk stratification and adjuvant therapy decisions 7
Do NOT forget fertility counseling in reproductive-aged patients—referral rates remain low despite guideline recommendations 4